[EN] QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4
申请人:RORER INTERNATIONAL (OVERSEAS) INC.
公开号:WO1989012629A1
公开(公告)日:1989-12-28
(EN) This invention relates to quinolinyl compounds of general formula (I), and the use of these compounds as pharmacological agents which are lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties and their pharmaceutical compositions and processes for this preparation.(FR) Cette invention concerne des composés de quinolinyle de formule générale (I), ainsi que l'emploi de ces composés en tant qu'agents pharmacologiques inhibiteurs de lipoxygénase et/ou antagonistes de leukotriène possédant des propriétés anti-inflammatoires et anti-allergiques. Elle concerne également leurs compositions pharmaceutiques et des procédés permettant cette préparation.
Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity
作者:Fu Chih Huang、Robert A. Galemmo、William H. Johnson、Gregory B. Poli、Matthew M. Morrissette、James J. Mencel、James D. Warus、Henry F. Campbell、George W. Nuss
DOI:10.1021/jm00166a017
日期:1990.4
on biological activity are discussed. Many of these compounds have highaffinity to the sulfidopeptide leukotriene D4 receptors with Ki values ranging between 2 and 20 nM and are orallyactive. Compound 27 [RG 12525, 5-[[2-[[4-(2-quinolinylmethoxy)phenoxy]- methyl]phenyl]methyl]-1H-tetrazole] represents the best combination of in vitro and in vivo biological activity in this series and has been selected